IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-06-16	1.200 kr	0.00%	577,307
26-06-15	1.200 kr	-3.38%	793,626
26-06-12	1.242 kr	-2.05%	65,122
26-06-11	1.268 kr	+2.42%	248,809
26-06-10	1.238 kr	-0.16%	68,834

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-06-16 pm EDT			5-day change	1st Jan Change
1.200 ^SEK	0.00%		-3.23%	-39.09%

Jun. 16	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
Jun. 16	Irlab highlights positive data for mesdopetam	FW

Market Cap	102M 10.9M 9.38M 8.63M 8.11M 15.24M 1.03B 15.41M 39.74M 506M 40.91M 40.04M 1.76B	P/E Ratio 2025 *	-	P/E Ratio 2026 *	-
Enterprise Value	102M 10.9M 9.38M 8.63M 8.11M 15.24M 1.03B 15.41M 39.74M 506M 40.91M 40.04M 1.76B	EV / Sales 2025	2.91x	EV / Sales 2026 *	1x
Free-Float	38.17%	Yield 2025 *	-	Yield 2026 *	-

Jun. 16	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
Jun. 16	Irlab highlights positive data for mesdopetam	FW
Jun. 08	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
Jun. 05	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI
Jun. 05	Irlab rights issue now 91 percent secured	FW
May. 06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
May. 06	Irlab reports growth in revenue and operating profit	FW
May. 06	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 05	Verisure climbs on earnings, OMXS30 index gains 1.2 percent	FW
May. 05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
May. 05	Irlab launches SEK 68 million rights issue	FW
May. 05	Irlab resolves on rights issue, obtains extended loan financing	RE
Apr. 17	Christer Nordstedt Declines Re-Election as Board Member of IRLAB Therapeutics AB	CI

Nov. 04	Redeye Lowers Fair Value for Irlab to 12 Kronor (from 17)	FW
24-05-13	Irlab rises almost double-digit - Redeye raises motivated value	FW
24-05-13	Redeye raises motivated value for Irlab to SEK 40 (35)	FW
24-02-12	Edison lowers motivated value for Irlab	FW
23-12-30	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

IRLAB Therapeutics AB Stock

Stocks

IRLAB A

SE0012675361

Pharmaceuticals

Valuation: IRLAB Therapeutics AB

Chart: IRLAB Therapeutics AB

Latest news : IRLAB Therapeutics AB

Last Transcript: IRLAB Therapeutics AB

Analysts' recommendations: IRLAB Therapeutics AB

Press Releases: IRLAB Therapeutics AB

News in other languages: IRLAB Therapeutics AB

Quotes and Performance

Course Extremes

Managers and Directors: IRLAB Therapeutics AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Jun. 16	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
Jun. 16	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
Jun. 05	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
Jun. 05	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ
Jun. 03	IRLAB Participates at Aktiedagarna in Stockholm on June 9	AQ

1 week	-3.23%
Current month	-1.80%
1 month	-3.85%
3 months	-24.72%
6 months	-36.84%
Current year	-39.09%

1 week	1.18	1.27
1 month	1.18	1.32
Current year	1.17	2.14
1 year	1.17	7.27
3 years	1.17	20.2
5 years	1.17	81.8
10 years	1.17	110

Manager	Title	Age	Since
Clas Sonesson CTO	Chief Tech/Sci/R&D Officer	65	2015-12-31
Susanna Waters PRN	Corporate Officer/Principal	60	2012-12-31
Kristina Torfgård CEO	Chief Executive Officer	63	2024-07-31

Director	Title	Age	Since
Rein Piir BRD	Director/Board Member	68	2015-12-31
Gunnar Olof Olsson CHM	Chairman	73	2020-05-06
Carola Elisabet Lemne CHM	Chairman	68	2023-02-19

Date	Insider	Type	Main position	Quantity	% Market Cap.
25-07-28	Carola Elisabet Lemne	Buy	Chairman	36,000	45.1264%
25-07-26	Kristina Torfgård	Buy	Chief Executive Officer	75,589	94.7516%
25-07-17	Joakim Tedroff	Buy	Chief Technology Officer	357,327	447.9129%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRLAB THERAPEUTICS AB	0.00%	-3.23%	-82.78%	-84.46%	10.87M
ELI LILLY AND COMPANY	-0.61%	-2.32%	+37.00%	+147.28%	1,007B
JOHNSON & JOHNSON	-0.20%	+1.30%	+49.70%	+43.64%	567B
ABBVIE INC.	+0.40%	-0.27%	+16.43%	+63.71%	392B
ROCHE HOLDING AG	-1.18%	+1.05%	+20.91%	+18.37%	328B
NOVARTIS AG	-0.43%	+2.01%	+23.20%	+32.46%	277B
ASTRAZENECA PLC	+0.64%	-3.71%	+20.92%	+13.67%	275B
NOVO NORDISK A/S	-1.86%	+3.05%	-45.70%	-49.24%	196B
AMGEN INC.	-0.77%	+0.61%	+17.82%	+52.27%	189B
GILEAD SCIENCES, INC.	+2.36%	-0.68%	+15.68%	+61.05%	154B
Average	-0.17%	-0.03%	+7.32%	+29.88%	338.61B
Weighted average by Cap.	-0.21%	-0.03%	+25.91%	+66.88%

	2025	2026 *
Net sales	56.3M 6.02M 5.18M 4.77M 4.48M 8.42M 570M 8.51M 21.95M 279M 22.59M 22.11M 973M	102M 10.91M 9.39M 8.64M 8.12M 15.25M 1.03B 15.42M 39.77M 506M 40.94M 40.06M 1.76B
Net income	-110M -11.73M -10.09M -9.29M -8.73M -16.4M -1.11B -16.58M -42.77M -544M -44.03M -43.09M -1.89B	-32.6M -3.49M -3M -2.76M -2.59M -4.87M -330M -4.93M -12.71M -162M -13.08M -12.8M -563M
Net Debt	-	-